PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Synamatix

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Synamatix Announces SynaWorks – A Next-generation Sequencing Bioinformatics Solutions Programme - Synamatix announced today the release of SynaWorks, its new bioinformatics solutions programme for handling data from next generation DNA sequencers
Synamatix Announces SynaWorks – A Next-generation Sequencing Bioinformatics Solutions Programme

 

NewswireToday - /newswire/ - Kuala Lumpur, Malaysia, 2008/06/24 - Synamatix announced today the release of SynaWorks, its new bioinformatics solutions programme for handling data from next generation DNA sequencers.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Synamatix announced today the release of SynaWorks, its new next-generation bioinformatics solutions programme. SynaWorks is a comprehensive suite of bioinformatics applications specifically tailored to manage and leverage data generated from a variety of next-generation sequencers.

Users will be able to take advantage of integrated bioinformatics applications that process, analyse, mine, assemble and visualise data from experiments such as whole-genome resequencing, transcriptome sequencing, ChIP-seq and de novo genome sequencing. Particular emphasis will be placed on helping researchers analyse data rapidly to identify and prioritise biologically significant findings.

Synamatix has optimised its solutions to handle a variety of data set types generated from the Roche Genome Sequencer FLX, Illumina’s Genome Analyzer and the SOLiD system from ABI. According to Synamatix General Manager, Dr Arif Anwar, “The aim of SynaWorks is to provide a comprehensive solution to scientists by managing and leveraging the huge amounts of DNA data generated from next-generation sequencers. We can assist with project design, provide bioinformatics know-how, analyse data according to individual requirements and, most importantly, work with researchers to help achieve meaningful scientific findings.”

While most solution providers mainly focus on handling genomics data, which includes moving, storing and archiving, Synamatix takes a different approach by offering a data analysis pipeline and platform that helps researchers maximise their research findings through data mining and visualisation.

About Synamatix
The fundamental technology underlying Synamatix R&D is the proprietary “SynaBASE” platform. Applications built upon this database platform exhibit significant improvement in analysis scalability, sensitivity and performance. Synamatix (synamatix.com) is a privately held bioinformatics company whose primary activities are ongoing R&D related to its core technology, and the support of its user base in the USA, Europe, Asia and Australia.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Synamatix

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Synamatix Announces SynaWorks – A Next-generation Sequencing Bioinformatics Solutions Programme

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Patricia Chan - Synamatix.com 
+603-22545676 enquiries[.]synamatix.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Synamatix securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Synamatix / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)